While the accuracy of raised ALT and AST as biomarkers of NASH is low (54), they are commonly utilized as clinical indicators of hepatocellular injury and improvement in these levels indicates improvement in fatty liver or NASH (55). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.